New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 6, 2019 - The FDA announced the approval of Jacobus’ Ruzurgi (amifampridine), for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.
Download PDF
Return to publications
